On October 18, 2024 cTRL Therapeutics, a biotechnology company advancing next-generation cell therapies for solid tumors, reported two upcoming poster presentations at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting 2024, taking place November 8-10 in Houston, TX (Press release, CTRL Therapeutics, OCT 18, 2024, View Source [SID1234647268]). These presentations will highlight the therapeutic potential of circulating tumor-reactive lymphocytes (cTRLs), isolated using cTRL’s proprietary IsoQore platform, as a transformative new treatment modality for solid tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of cTRL’s poster presentations at SITC (Free SITC Whitepaper) are as follows:

Title: Anti-tumor activity of circulating tumor-reactive lymphocytes (cTRLs) isolated from checkpoint-refractory melanoma patients that failed TIL manufacturing.
Abstract Number: 401
Date and Time: Friday, November 8, from 9:00 a.m. to 7:00 p.m. CST
Location: Exhibit Halls A & B, George R. Brown Convention Center
Title: Circulating tumor-reactive lymphocytes (cTRLs) isolated from colorectal cancer (CRC) patients are reactive against autologous tumors and show less exhaustion than tumor-infiltrating lymphocytes (TILs).
Abstract Number: 400
Date and Time: Saturday, November 9, from 9:00 a.m. to 7:00 p.m. CST
Location: Exhibit Halls A & B, George R. Brown Convention Center